The cumulative probability of sustained IOP elevation or of initiation or augmentation of ocular hypotensive therapy by 3 years , after repeated ranibizumab injections , was 9.5 % for the participants who received ranibizumab plus prompt or deferred focal/grid laser treatment vs 3.4 % for the participants who received a sham injection plus focal/grid laser treatment ( difference , 6.1 % [ 99 % CI , -0.2 % to 12.3 % ] ; hazard ratio , 2.9 [ 99 % CI , 1.0-7 .9 ] ; P = .01 ) .